Autonomic nervous system dysfunction in idiopathic REM sleep behavior disorder as a short-term risk for a synucleinopathy
Journal of Neurology · 2025
DOI: 10.1007/s00415-024-12787-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurology, 2025. Verfasst von Judith Navarro-Otano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Service, Hospital Clínic, Barcelona, Spain. Jnavarr1@clinic.cat. Hauptthemen laut MEDLINE: REM Sleep Behavior Disorder, Synucleinopathies, Autonomic Nervous System Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Idiopathic REM sleep behavior disorder (iRBD) is a prodromal marker of the alpha-synucleinopathies, in which autonomic nervous system (ANS) involvement may occur. We aimed to characterize the presence and severity of subjective and objective ANS dysfunction in iRBD and assess its capacity to predict short-term clinical progression to a synucleinopathy. METHODS: Prospective study of patients with polysomnography-confirmed iRBD in whom symptomatic ANS involvement was assessed using the Composite Autonomic Symptom Score (COMPASS-31) and objective dysfunction with the Composite Autonomic Severity Score (CASS). Baseline ANS data were compared between those who later developed a synucleinopathy and those who did not. RESULTS: We evaluated 25 subjects with iRBD without risk factors for autonomic neuropathy and at least 6 months of follow-up (mean: 19 months). At the end of the study, seven (28%) patients developed a synucleinopathy, namely Parkinson's disease (n = 5) and dementia with Lewy bodies (n = 2). 73.7% of patients had COMPASS-31 scores above the normal cut-off, while no score differences regarding phenoconversion status were observed. At baseline, 85.7% of the subjects who phenoconverted exhibited at least one abnormal result in the CASS score, compared to 38.9% of subjects who remained disease-free (p = 0.035). Adrenergic dysfunction evaluated by an impaired overshoot in Valsalva phase IV and by pressure recovery time was associated with the development of overt synucleinopathy (p = 0.032 and 0.033, respectively). CONCLUSION: Symptomatic and subclinical ANS dysfunctions are common in iRBD. ANS dysfunction affecting mainly the adrenergic system seems to be a short-term risk for the development of a synucleinopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neurology Service, Hospital Clínic, Barcelona, Spain. Jnavarr1@clinic.cat.
- Institut d'Investigacions Biomèdiques August Pi I Sunyer, - IDIBAPS, Barcelona, Spain. Jnavarr1@clinic.cat.
- Neurology Service, Hospital Clínic, Barcelona, Spain.
- Neurology Service, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau, Barcelona, Spain.
- Sleep Unit, Neurology Service, Hospital Clínic Barcelona, IDIBAPS, Barcelona, Spain.
- Sleep Unit, Neurology Service, Hospital Clínic Barcelona, Universitat de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.
Zitieren
APA
Navarro-Otano, J., Llansó, L., Alejaldre, A., Diez, L., Santamaría, J., & Iranzo, A. (2025). Autonomic nervous system dysfunction in idiopathic REM sleep behavior disorder as a short-term risk for a synucleinopathy. Journal of Neurology. https://doi.org/10.1007/s00415-024-12787-2
Vancouver
Navarro-Otano J, Llansó L, Alejaldre A, Diez L, Santamaría J, Iranzo A. Autonomic nervous system dysfunction in idiopathic REM sleep behavior disorder as a short-term risk for a synucleinopathy. Journal of Neurology. 2025. doi:10.1007/s00415-024-12787-2
BibTeX
@article{NavarroOtano2025,
author = {Navarro-Otano, Judith and Llansó, Laura and Alejaldre, Aida and Diez, Laura and Santamaría, Joan and Iranzo, Alex},
title = {Autonomic nervous system dysfunction in idiopathic REM sleep behavior disorder as a short-term risk for a synucleinopathy},
journal = {Journal of Neurology},
year = {2025},
doi = {10.1007/s00415-024-12787-2}
}
EUVIMED